Day: August 24, 2020

FRANKFURT, Deutschland, Aug. 24, 2020 (GLOBE NEWSWIRE) — Im Zuge der COVID-19-Pandemie sehen sich Unternehmen in Deutschland derzeit mit strengeren Datenschutzbestimmungen und neuen Cyber-Gefahren konfrontiert. Vor diesem Hintergrund wenden sie sich verstärkt an Service-Anbieter, um ihre Cyber-Sicherheit zu verbessern. Dies meldet eine heute veröffentlichte Studie der Information Services Group (ISG) (Nasdaq: III), ein führendes globales Marktforschungs- und Beratungsunternehmen im Technologiesegment.Dem „ISG Provider Lens™ Cyber Security – Solutions & Services Report Germany 2020“ zufolge steigt die Nachfrage nach Cyber-Security-Diensten derzeit, da mehr und mehr Geschäftsprozesse digitalisiert werden und die Nutzung des Industrial Internet of Things weiter ansteigt.Darüber hinaus führt die Datenschutzgrundverordnung (DSGVO)...

LUND, Sweden, Aug. 24, 2020 (GLOBE NEWSWIRE) — Clinical Laserthermia Systems AB (publ) (CLS), developer of innovative image-guided laser ablation technology for minimally invasive soft tissue and cancer tumor treatment, and Advanced Medical Systems Pte Ltd (AMS), a high-end provider of medical devices, systems, and services for the Asia-Pacific region. The companies have entered into a collaborative agreement where the parties through a joint venture company, Clinical Asia Pacific Pte. Ltd., will launch the TRANBERG® Thermal Therapy System and imILT®treatment protocol in the rapidly growing Asia-Pacific market. The first step is to initiate the regulatory processes and market preparations needed in order to successfully launch CLS’ products and therapy in the region.“Clinical Asia Pacific is ready to start its operation in Singapore...

AB Linas Agro Group received the notification from Andrius Pranckevičius  on disposal of voting rights (see attachment). The reason for crossing the threshold – changes in legal regulation. The declared threshold that was crossed – 5%.For more information please contact Finance Director Mažvydas Šileika, mob.  +370 619 19 403, e-mail m.sileika@linasagro.lt.AttachmentNotification on the disposal of the voting rights_Andrius_Pranckevicius

Serstech today received a 5.3 MSEK order from its Asian partner DKSH. DKSH will deliver the products to a national narcotics police organization in South-East Asia. The order consists of the Serstech 100 Indicator and ChemDash software and will be delivered and invoiced in Q3 2020.The order is based on a tender that was cancelled in Q2 due to the uncertainties created by the Corona pandemic. The tender was reopened again recently, since the police needed to get access to modern tools to battle the problems with narcotics – problems that have escalated over the last few months.“DKSH has been a Serstech sales partner since early 2019 and has more than 100 years of experience in the Asian markets. Getting such an order so quickly is a testament to their skills and deep understanding of their market”, says Serstech CEO Stefan Sandor.“Serstech...

HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place on September 17-21, 2020.Further details of the presentations are as follows:SURUFATINIB

PRESS RELEASE24 August 2020Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that a poster highlighting results from a phase 2 clinical trial of Tesomet for hypothalamic obesity will be presented at the 22nd European Congress of Endocrinology virtual annual meeting being held 5-9 September 2020. Professor Ulla Feldt-Rasmussen, M.D. DMSc (Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital) will present the poster titled “A Randomized-Controlled Trial of Tesomet Resulted in Significant Weight Loss in Hypopituitary Patients with Hypothalamic Obesity”.For more information, please contactRudolf Baumgartner, CMO & Head of Clinical Development, Saniona, Email: rudolf.baumgartner@saniona.comThe information was submitted for publication,...

PRESSMEDDELANDE24 augusti 2020Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att en poster som illustrerar resultaten från en Fas 2-studie med Tesomet mot hypotalamisk fetma kommer att presenteras vid e-ECE-2020, den europeiska endokrinologikongressen, som i år hålls virtuellt 5-9 september. Professor Ulla Feldt-Rasmussen, M.D. DMSc (Avdelningen för medicinsk endokrinologi och metabolism, Rigshospitalet, Köpenhamns Universitetssjukhus) kommer att presentera postern, som fått rubriken “A Randomized-Controlled Trial of Tesomet Resulted in Significant Weight Loss in Hypopituitary Patients with Hypothalamic Obesity”.För mer information, var vänlig kontaktaRudolf Baumgartner, CMO & Head of Clinical Development, Saniona, E-post: rudolf.baumgartner@saniona.comInformationen...

Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.  ABN AMRO announces call of EUR 1.0bn AT1 instrument (XS1278718686)With reference to the Terms and Conditions of the EUR 1.0 billion 5.75% Undated Deeply Subordinated Additional Tier 1 Fixed Rate Resettable Callable Capital Securities callable on 22 September 2020 and issued under a stand-alone prospectus dated 18 September 2015 with ISIN XS1278718686 ABN AMRO announces to exercise its right to redeem these Capital Securities in full on 22 September 2020. Trading will be suspended as of 18 September 2020.ABN AMRO Press Office                                         ABN AMRO Investor RelationsJarco de Swart                                  ...

Dit bericht mag geheel noch gedeeltelijk worden vrijgegeven, gepubliceerd of verspreid in, naar of vanuit enige jurisdictie waar dit zou worden aangemerkt als een overtreding van de aldaar geldende wet- of regelgeving.ABN AMRO kondigt aflossing aan van Additional Tier 1-instrument van EUR 1,0 miljard (XS1278718686)Onder verwijzing naar de voorwaarden van de EUR 1,0 miljard Undated Deeply Subordinated Additional Tier 1 Fixed Rate Resettable Callable Capital Securities (ISIN XS1278718686) aflosbaar op 22 september 2020 en uitgegeven onder een stand-alone prospectus met datum 18 september 2015, kondigt ABN AMRO aan dat zij haar recht uitoefent om deze Capital Securities volledig af te lossen op 22 september 2020. De handel in deze Capital Securities wordt op 18 september 2020 beëindigd.Dit persbericht is gepubliceerd door ABN AMRO Bank  N.V....

LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new subgroup analysis from Phase 2b trials with nebulized ensifentrine in chronic obstructive pulmonary disease (“COPD”) at the European Respiratory Society (“ERS”) International Congress on Tuesday, September 8, 2020. The abstracts are available on the ERS website and will be published in a supplement of the September 2020 edition of the peer reviewed journal, European Respiratory Journal.Tara Rheault, Vice President, R&D and Global Project Management at Verona Pharma, will present subgroup analysis of Phase 2b data, first reported by Verona Pharma on January 13, 2020, and March 26, 2018, demonstrating...